- Home
- YALA vs PCRX Comparison
YALA vs PCRX Comparison
Compare YALA & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YALA | PCRX |
|---|---|---|
| Founded | 2016 | 2006 |
| Country | United Arab Emirates | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2020 | 2010 |
Fundamental Metrics
Financial Performance| Metric | YALA | PCRX |
|---|---|---|
| Price | $6.57 | $22.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $35.33 |
| AVG Volume (30 Days) | 194.6K | ★ 736.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 107.44 |
| EPS | N/A | ★ 0.16 |
| Revenue | N/A | ★ $541,533,000.00 |
| Revenue This Year | $3.07 | $9.77 |
| Revenue Next Year | $11.99 | $9.71 |
| P/E Ratio | ★ $8.76 | $140.38 |
| Revenue Growth | N/A | ★ 26.04 |
| 52 Week Low | $4.42 | $18.80 |
| 52 Week High | $9.29 | $27.99 |
Technical Indicators
Market Signals| Indicator | YALA | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 31.95 | 52.95 |
| Support Level | $6.13 | $20.41 |
| Resistance Level | $7.32 | $23.82 |
| Average True Range (ATR) | 0.22 | 1.01 |
| MACD | -0.06 | 0.02 |
| Stochastic Oscillator | 14.29 | 68.81 |
Price Performance
Historical ComparisonAbout YALA Yalla Group Limited each representing one
Yalla Group Ltd is a MENA-based online social networking and gaming company. It operates two flagship mobile applications, Yalla, a voice-centric group chat platform, and Yalla Ludo, a casual gaming application featuring online versions of board games popular in MENA, with in-game voice chat and localized majlis functions. The Group has one operating segment, which is the social networking and entertainment platform.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.